BioSpace News Archive

First-quarter 2021 earnings conference call on Tuesday, April 27, 2021, at 8 a.m. CDT. The earnings call can be accessed at (800) 762-2596 within the U.S. or +1 (212) 231-2916 outside the U.S.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.

A chemical known to protect nerve cells also slows glaucoma, the leading cause of irreversible blindness, results of a new study in rats show.

Leading biofacturing company Zymergen has named Jay Flatley as the Chairman of the Board of Directors, effective immediately.

The Ireland-based pharmacy group has put together a robust online presence, complete with an online store that offers consumers hundreds of products spread over several categories.

Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a biotechnology company developing next-generation bioengineered esophageal implants, today announced its financial results for the three and twelve months ended December 31, 2020.

CM Life Sciences II Inc. (Nasdaq: CMIIU) (the “Company”) today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about April 15, 2021.

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, plans to announce financial results for the second quarter fiscal year 2021 after market close on Monday, May 10, 2021.

Bruker Corporation announced preliminary revenue for the first quarter ended March 31, 2021 in a range of $549 - $554 million, representing reported revenue growth of approximately 30% to 31%, compared to the first quarter of 2020.

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.